|  |  |
| --- | --- |
|  | **NHS Prescription Services**Bridge House152 Pilgrim StreetNewcastle upon TyneNE1 6SN0845 850 0001 Email:nhsbsa.prescriptionservices@nhsbsa.nhs.ukWebsite:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  20 May 2024 |
|  |

VERSION 5.2.0

Dear dm+d User,

**SNOMED International Proposal to Increase Description Length Limit**

SNOMED International are proposing to increase the maximum length of Fully Specified Name and Synonym descriptions from 255 to 4096 characters.

As the UK Member’s National Release Centre, NHS England is collating feedback from SNOMED CT users in the UK on behalf of SNOMED International.

For further information about the proposal and to submit your feedback, go to the [Delen news article](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1061497&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136)

The deadline for survey responses is **5pm on Wednesday, 31 July 2024**.

**dm+d and SNOMED CT UK Drug Extension terminology Quality Service Improvements (QSIs)**

Following the work to make changes to dm+d and SNOMED CT UK Drug Extension which is still being finalised, the UK Medicines Terminology Strategy Group which is overseeing the project has approved a number of Quality and Service Improvements (QSIs) to focus on during 2024-2025.

To view details of all the planned changes to dm+d and SNOMED CT UK Drug Extension terminologies, the QSIs and the delivery timeline visit [our webpage](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies) for the latest information.

The first QSI to go-live will be the addition of dm+d links to BNF codes within the Terminology Server. This means the same BNF links from dm+d will be available in TRUD and the Terminology Server at the same time in future.

This is scheduled to be available in June. The exact go-live date will be confirmed in future Release notes and the website will be also updated.

If you have any specific queries relating to the dm+d and SNOMED CT UK Drug Extension changes, please contact nhsdigital.ukmeds@nhs.net.

**SNOMED International consultation on the inactivation of Role Groupers in Substance and Medicinal Product Hierarchies**

Following the [consultation](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=994809&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) SNOMED International ran up to the end of January regarding the ‘Inactivation of Role Groupers in Substance and Medicinal Product Hierarchies’, their Content Team has released their ‘Universal Summary of all feedback received’ document which can be found [here](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1047481&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136).

Under the ‘**Resolution and Next Steps**’ section of the document:

* The Substance role groupers will remain in situ with no change.
* A disclaimer will be added to the SNOMED CT Editorial Guide related to known issues with use of Substance role groupers including potential incorrect classification.
* A Briefing Note will follow regarding the inactivation of Medicinal Product therapeutic role groupers

The next step is for NHS England to circulate the Briefing Note regarding the ‘inactivation of Medicinal Product therapeutic role groupers’ and communicate next steps relating to this.

If you have any questions, please email information.standards@nhs.net

**Monthly dm+d Supplier Workshop**

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries.  It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact medicinestandards@nhs.net for more information.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |
| --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported  |  14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order |  21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported |  27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported |  27/03/2023 |
| Pethidine 50mg tablets | 42161611000001107 | Imported (United States) |  14/08/2023 |
| Permethrin 5% cream | 42243511000001101 | Imported |  18/09/2023 |
| Vyvanse 40mg capsules | 42409611000001105 | Imported |  13/11/2023 |
| Lisdexamfetamine 40mg capsules | 42415411000001107 | Imported |  20/11/2023 |
| Bumetanide 5mg tablets | 42440611000001105 | Imported |  27/11/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) |  27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) |  27/11/2023 |
| Lamotrigine 5mg dispersible tablets sugar free | 41526311000001107 | Imported |  27/11/2023 |
| Dicycloverine 10mg/5ml oral solution | 42491411000001108 | Imported (United States) |  11/12/2023 |
| Diazepam 2mg/5ml oral suspension sugar free | 42495311000001104 | Special Order |  11/12/2023 |
| Hydrogen peroxide 3% solution  | 42510811000001109 | Imported |  18/12/2023 |
| Lisdexamfetamine 60mg capsules | 42640611000001108 | Imported |  19/02/2024 |
| Methadone 5mg tablets | 42641811000001104 | Imported |  19/02/2024 |
| Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose vials  | 42642011000001102 | Imported |  19/02/2024 |
| Mesalazine 400mg gastro-resistant tablets | 42836111000001108 | Imported |  20/05/2024 |
| Guanfacine 2mg modified-release tablets | 42836611000001100 | Imported |  20/05/2024 |
| Guanfacine 3mg modified-release tablets | 42836911000001106 | Imported |  20/05/2024 |

**Invalidations**

The following concepts have been invalidated. The reason for the invalidation is that these pack sizes were authored erroneously. Pack sizes for such concepts should not be based on bottle sizes. The dm+d Content Committee has decided that in this scenario, the most pragmatic decision is to author pack sizes based on the volumes of water to be added for reconstitution.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Rivaroxaban 1mg/ml oral suspension sugar free (VMP not being invalidated) | **VMP**No replacement but will be changing name from 1.4.24 to:Rivaroxaban 1mg/ml granules for oral suspension sugar free |
| **VMP SNOMED ID**39609211000001101 | **VMP SNOMED ID**N/A |
| **VMPP**250ml | **VMPP**N/A |
| **VMPP SNOMED ID**39504911000001100 | **VMPP SNOMED ID**N/A |
| **AMP**Xarelto 1mg/ml granules for oral suspension (Bayer Plc) (AMP not being invalidated) | **AMP**N/A |
| **AMP SNOMED ID**39505011000001100 | **AMP SNOMED ID**N/A |
| **AMPP**100ml | **AMPP**50ml |
| **AMPP SNOMED ID**39505111000001104 | **AMPP SNOMED ID**42699611000001105 |
| **AMPP**250ml | **AMPP**100ml |
| **AMPP SNOMED ID**39505211000001105 | **AMPP SNOMED ID**42699511000001106 |

**Advance Notice of Invalidations**

The following concepts will be invalidated mid-June. The reason for the invalidation is that these pack sizes were authored erroneously. Pack sizes for such concepts should not be based on bottle sizes. The dm+d Content Committee has decided that in this scenario, the most pragmatic decision is to author pack sizes based on the volumes of water to be added for reconstitution.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Dasatinib 10mg/ml oral suspension (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**37223211000001104 | **VMP SNOMED ID**N/A |
| **VMPP**99ml | **VMPP**90ml |
| **VMPP SNOMED ID**37221811000001102 | **VMPP SNOMED ID**42759611000001106 |
| **AMP**Sprycel 10mg/ml oral suspension (Imported (Germany)) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**37221911000001107 | **AMP SNOMED ID**N/A |
| **AMPP**99ml | **AMPP**90ml |
| **AMPP SNOMED ID**37222011000001100 | **AMPP SNOMED ID**42759711000001102 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Mycophenolate mofetil 1g/5ml oral suspension sugar free(VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**4897811000001103 | **VMP SNOMED ID**N/A |
| **VMPP**175ml | **VMPP**160ml |
| **VMPP SNOMED ID**4881111000001102  | **VMPP SNOMED ID**42760011000001103 |
| **AMP**Cellcept 1g/5ml oral suspension (Roche Products Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**4881311000001100 | **AMP SNOMED ID**N/A |
| **AMPP**175ml | **AMPP**160ml |
| **AMPP SNOMED ID**4881411000001107 | **AMPP SNOMED ID**42760111000001102 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Oseltamivir 6mg/ml oral suspension sugar free(VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**21525811000001108 | **VMP SNOMED ID**N/A |
| **VMPP**65ml | **VMPP**50ml |
| **VMPP SNOMED ID**21525011000001102 | **VMPP SNOMED ID**42760811000001109 |
| **AMP**Tamiflu 6mg/ml oral suspension (Roche Products Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**21525111000001101 | **AMP SNOMED ID**N/A |
| **AMPP**65ml | **AMPP**50ml |
| **AMPP SNOMED ID**21525211000001107 | **AMPP SNOMED ID**42760911000001104 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Valganciclovir 50mg/ml oral solution sugar free (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**15362311000001103 | **VMP SNOMED ID**N/A |
| **VMPP**100ml | **VMPP**88ml |
| **VMPP SNOMED ID**15354811000001108 | **VMPP SNOMED ID**42760411000001107 |
| **AMP**Valcyte 50mg/ml oral solution (Neon Healthcare Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**15354911000001103 | **AMP SNOMED ID**N/A |
| **AMPP**100ml | **AMPP**88ml |
| **AMPP SNOMED ID**15355011000001103 | **AMPP SNOMED ID**42760511000001106 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Sildenafil 10mg/ml oral suspension sugar free (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**21705011000001109 | **VMP SNOMED ID**N/A |
| **VMPP**112ml | **VMPP**90ml |
| **VMPP SNOMED ID**21700111000001102 | **VMPP SNOMED ID**42760611000001105 |
| **AMP**Revatio 10mg/ml oral suspension (Viatris UK Healthcare Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**21700211000001108 | **AMP SNOMED ID**N/A |
| **AMPP**112ml | **AMPP**90ml |
| **AMPP SNOMED ID**21700311000001100 | **AMPP SNOMED ID**42760711000001101 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Voriconazole 200mg/5ml oral suspension (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**41772711000001109 | **VMP SNOMED ID**N/A |
| **VMPP**75ml | **VMPP**70ml |
| **VMPP SNOMED ID**7961111000001103 | **VMPP SNOMED ID**42760211000001108 |
| **AMP**VFEND 40mg/ml oral suspension (Pfizer Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**7961211000001109 | **AMP SNOMED ID**N/A |
| **AMPP**75ml | **AMPP**70ml |
| **AMPP SNOMED ID**7961311000001101 | **AMPP SNOMED ID**42760311000001100 |

The following concepts will be invalidated mid-June. The reason for these invalidations is that these pack sizes were authored erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Clopidogrel 75mg tablets (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**39689111000001106 | **VMP SNOMED ID**N/A |
| **VMPP**14 tablet | **VMPP**N/A |
| **VMPP SNOMED ID**40314711000001101 | **VMPP SNOMED ID**N/A |
| **AMP**Clopidogrel 75mg tablets (Medreich Plc) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**40314811000001109 | **AMP SNOMED ID**N/A |
| **AMPP**14 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**40314911000001104 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Ivabradine 5mg tablets (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**9831411000001101 | **VMP SNOMED ID**N/A |
| **VMPP**28 tablet | **VMPP**N/A |
| **VMPP SNOMED ID**41728811000001103 | **VMPP SNOMED ID**N/A |
| **AMP**Ivabradine 5mg tablets (Medreich Plc) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**41728711000001106 | **AMP SNOMED ID**N/A |
| **AMPP**28 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**41729011000001104 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Paroxetine 10mg tablets (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**39701911000001102 | **VMP SNOMED ID**N/A |
| **VMPP**14 tablet | **VMPP**N/A |
| **VMPP SNOMED ID**42446511000001108 | **VMPP SNOMED ID**N/A |
| **AMP**Paroxetine 10mg tablets (Medreich Plc) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**35851411000001109 | **AMP SNOMED ID**N/A |
| **AMPP**14 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**42446711000001103 | **AMPP SNOMED ID**N/A |

The following concept will be invalidated mid-June. The reason for this invalidation is that this product was authored erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Ivabradine 7.5mg tablets (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**9831511000001102 | **VMP SNOMED ID**N/A |
| **VMPP**28 tablet | **VMPP**N/A |
| **VMPP SNOMED ID**41729311000001101 | **VMPP SNOMED ID**N/A |
| **VMPP**56 tablet (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**9830111000001100 | **VMPP SNOMED ID**N/A |
| **AMP**Ivabradine 7.5mg tablets (Medreich Plc) | **AMP**N/A |
| **AMP SNOMED ID**41729111000001103 | **AMP SNOMED ID**N/A |
| **AMPP**28 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**41729411000001108 | **AMPP SNOMED ID**N/A |
| **AMPP**56 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**41729211000001109 | **AMPP SNOMED ID**N/A |

dm+d Authoring Team